Pfizer doing SARS-COV2 Gain of Function

Dejmo tole tle pustiti, ker ni drugih aktivnih tem.

https://arstechnica.com/science/202...-heart-attack-stroke-after-covid-study-finds/

(Ja, ja sej vem, big pharma, fejk itd)

Sem že lepil članke, kjer je bilo ugotovljeno, da covid povzroči srčni napad s 7x večjo verjetnostjo kot cepljenje. Pa se bebčki samo režijo.

Uporabnik AndY1 je napisal:

Cesa vam Pfizer, zdravstvene ustanove in johan_blond niso povedali o mRNA cepivih (iz avstralskega senata):

Klikni za razširitev

Ko me že po nemarnem omenjaš, tebi tako ljubi ivermectin .

Rezulatati dvojne slepe študije, na spodobnem vzorcu 1200 ljudi (602 + 604) ni nobene razlike med placebo skupino in skupino, ki je dobila kar konreten odmerek ivermectina (600 μg/kg; 6 dni, tebi tako ljubi FLCCC je priporočal od 400 do 600 μg/kg vsaj 5 dni).

NOBENEGA VPLIVA IVERMECTINA, oziroma statisitčno ovrednotena verjetnost, da ivermectin skrajša COVID za samo EN dan je 0,1 %

Če pa Malone... Pa big pharma...

Ko se pohojena triperesna deteljica spet oglasi.
Neprecenljivo.

To, kar si ti prilepil je razkritje potencialnih konfliktov. In američani so kar striknti pri teh zadevah (ne tako kot pri nas, ko kdo "administrativno" pozabi kaj prijavit oziroma razkriti).

To, da je nekdo delal na projektu, ki je bil financiran iz (ali tudi) industrijkega denarja ni noben konflikt interesov (reported receiving grants).
NCATS in NIH sta itak državni inštituciji.
ACTIV-6 protocol pa je tisto, kar si si ves čas tako želel: drug repuroposing, ki so ga vodile akademske inštitucije (https://clinicaltrials.gov/ct2/show/NCT04885530)
Edini potencialni konflikt interesov so potencionalno personal fees. Če pogledaš npr. personal fees from Theratechnologies, pa vidiš da se itak ukvajrajo s terapijo HIV (outside the submitted work)
Če pogledaš skozi "tošl" boš videl, da so vsi tako tebi ljubi viri informacij (Malone, ...) veliko bolj v konfliktu interesov, kajti nihovo medijsko delovanje je direktno povezano z njihovim osebnim profitom.

Realni razlog za takšno število potencialnih razkritij pa da večina teh ljudi (pa nisem šel vsakega posebej preverjat) so pravzaprav ljudje, ki so zaposleni na univerzah/inštitutih in se ukvarjajo s kliničnimi študijami (takšnimi in drugačnimi) (na dnu imaš navedeno njihovo affiliacijo).
Industrija ne izvaja sama kliničnih študij ampak mora izbrat neko inštitucijo, ki bo v njihovem imenu izvedla študijo, seveda pa jo mora plačat- in to je potem ta vir finančnega toka.

Jaz bom moral v kratkem iti na tehnični pregled, ki ga bom JAZ plačal. A je posledično tehnični pregled sploh smiseln, če pa so "na mojem plačilnem listu".
Podobnih konfliktov interesov je precej več kot si ti misliš, je pa bilo tudi tukaj velikokrat objavljeno, kako so ti "neodvisni razkrikovalci" v veliko, veliko večjem konfliktu interesov, in precej bolj finančno odvisni od tega kar počno, kot pa ti ki so navedeni.

Conflict of Interest Disclosures: Dr Naggie reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study and receiving grants from Gilead Sciences and AbbVie; receiving personal fees from Pardes Biosciences and Silverback Therapeutics for consulting; serving as a scientific advisor for and having stock options in Vir Biotechnology; receiving personal fees from and serving on a data and safety monitoring board for Personal Health Insights; and serving on an event adjudication committee for Bristol Myers Squibb/PRA Health Sciences outside the submitted work. Dr Boulware reported receiving grants from the NIH (#U24TR001608) as co-chair of the ACTIV-6 trial steering committee during the conduct of the study. Dr Lindsell reported receiving grants to the institution from the National Center for Advancing Translational Sciences (NCATS) to the institution during the conduct of the study and grants to the institution from NIH and Department of Defense and research funds to the institution from the CDC, bioMerieux, AstraZeneca, AbbVie, Entegrion Inc, and Endpoint Health outside the submitted work; having a patent for risk stratification in sepsis and septic shock issued to Cincinnati Children's Hospital Medical Center; and having stock options in Bioscape Digital unrelated to the current work. Dr Stewart reported receiving grants from Duke University as a subaward for ACTIV-6 from NIH during the conduct of the study and grants from NIH supported by grants from NCATS and NIDDK and research support from the Abdominal Core Health Quality Collaborative, a 501(c)(3) nonprofit organization, outside the submitted work. Dr Lim reported receiving a subaward from NCATS to the institution during the conduct of the study. Dr Gentile reported receiving personal fees from Duke University for ACTIV-6 protocol development committee membership during the conduct of the study. Dr Felker reported receiving grants from NIH during the conduct of the study. Dr Jayaweera reported receiving grants from NCATS during the conduct of the study and grants from Gilead, ViiV Healthcare, and Janssen and personal fees from Theratechnologies outside the submitted work. Dr Sulkowski reported receiving grants to the institution from Janssen, Vir, and GSK; personal fees for serving on a scientific advisory board from GSK, AbbVie, Antios, Assembly Bio, Atea, Gilead; personal fees for serving on a data and safety monitoring board from Precision Bio and Immunocore; personal fees as an editor for Journal of Viral Hepatitis; and personal fees from NIH (K24DA034621) outside the submitted work. Dr Rothman reported receiving grants from the NIH during the conduct of the study and spouse owning a small amount of stock in Moderna. Dr Wilson reported receiving grants from NCATS (3U24TR001608) during the conduct of the study. Dr DeLong reported receiving grants from NCATS (3U24TR001608) during the conduct of the study. Dr Collins reported receiving grants from NCATS during the conduct of the study and personal fees from Vir Biotechnology and Enanta Pharmaceuticals and grants from NHLBI outside the submitted work. Dr Adam reported receiving US Government funding through Operation Warp Speed during the conduct of the study. Dr Hanna reported receiving grants from US Biomedical Advanced Research & Development Authority contract to Tunnell Government Services for consulting services during the conduct of the study and personal fees from Merck & Co and AbPro outside the submitted work. Dr Ginde reported receiving contracts from NIH during the conduct of the study and grants from NIH, Centers for Disease Control and Prevention, Department of Defense, Faron Pharmaceuticals, and AbbVie outside the submitted work. Dr Castro reported receiving grants from NIH during the conduct of the study and grants from ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance and personal fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, GSK, and Regeneron and having stock options in Aer Therapeutics outside the submitted work. Dr McTigue reported receiving grants from University of Pittsburgh for ACTIV-6 research funding during the conduct of the study. Dr Hernandez reported receiving grants from AstraZeneca, Merck, and Pfizer outside the submitted work. No other disclosures were reported.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
Department of Medicine, Duke University School of Medicine, Durham, North Carolina
Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis
Vanderbilt University Medical Center, Nashville, Tennessee
School of Data Science, University of Virginia, Charlottesville
Clinical Trials Center of Middle Tennessee, Franklin
University Medical Center New Orleans, Louisiana State University Health Sciences Center, New Orleans
Jadestone Clinical Research, LLC, Silver Spring, Maryland
David Kavtaradze, Inc, Cordele, Georgia
Lakeland Regional Medical Center, Lakeland, Florida
Focus Clinical Research Solutions, Charlotte, North Carolina
Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida
Weill Cornell Medicine, New York, New York
Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland
Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Nashville
National Center for Advancing Translational Sciences, Bethesda, Maryland
Foundation for the National Institutes of Health, Bethesda, Maryland
Stakeholder Advisory Committee, Pittsburgh, Pennsylvania
Biomedical Advanced Research and Development Authority, Washington, DC
University of Colorado School of Medicine, Aurora
Division of Pulmonary, Critical Care and Sleep Medicine, University of Missouri-Kansas City School of Medicine, Kansas City
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville

Saj ne pričakuješ, da bo razumel?

Andy1, saj ne pričakuješ, da bo razumel.

Mi ne pričakujemo, ampak vemo, da vi2 ne bosta razumela .

Uporabnik AndY1 je napisal:

Ves kaj pa razumem? Da so v konfliktih interesov navedena podjetja, ki jim ni v interesu, da obstaja ze obstojece zdravilo kot npr
Gilead (Remdesivir)
AstraZeneca (cepivo)
Janssen (J&J cepivo)
a small amount of stock in Moderna
Merck (molnupiravir)
Pfizer (mRNA cepivo)

outside the submitted work - ja in ce bo hotel dobiti se kaj grantov od teh podjetij, bo pel tako, kot mu recejo. Saj vemo kako gre ta igra, kajne?

Klikni za razširitev

Zakaj ne? A zdravila bi pa senkal? V interesu je vse, kae se proda.

Drugaca pa pa pojma nimas, kako gre ta igra. Ves, kako bi se jo sel ti, ampak to je pa vse in povsem nerelevantno.

Evo, sedaj pa res lahko še dokončno izolacije in maske ukinejo...

Do naslednjič, ko boste spet prtičke na nos natikal in verjeli v ekstremno učinkovitost.

Evo we are back

Skupaj s tabo smo še vsi živi, le da si ti imel dve leti omejitev, mi pa smo vsaj eno leto od tega živeli "normalno".

Uporabnik Samo Izoliranc je napisal:

Skupaj s tabo smo še vsi živi, le da si ti imel dve leti omejitev, mi pa smo vsaj eno leto od tega živeli "normalno".

Klikni za razširitev

Dodaj še mnoge možganske poškodbe necepljenih, kot je on, ker toliko belih mišk ne more niti preštet.